Stock Market News2 months J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC Zacks
If approved, JNJ’s Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
XIf approved, JNJ’s Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
X